Clinical trials depend upon the participation of individuals who volunteer sometimes to access medicines but often to help science advance for the benefit of future patients; each trial, therefore, should be valuable and important. But how can one know if a trial will be important or even informative before results are published? In this proposal, the team will investigate the ethical and practical implications of including an assessment of scientific value and informativeness in decisions regarding the initiation or continuation of clinical trials.
Our Grants
Preventing the initiation of, and deprioritizing the continuation of, uninformative clinical trials
Barbara Bierer, MD
Brigham and Women's Hospital
Brigham and Women's Hospital
Grant Type
Making a Difference
Grant Cycle
fall 2020
Duration
24 months
Amount
$207,222
-
Barbara E Bierer, Deborah A Zarin, & Luke Gelinas, Deprioritization of Ongoing Clinical Trials, Ethics & Human Research, Oct 2023
Read more -
Nora Hutchinson et al., Disclosure of Possible Trial Termination to Participants of Interventional Clinical Trials, JAMA, Apr 2023
Read more -
Luke Gelinas et al., How to limit uninformative trials: Results from a Delphi working group, Med (Cell Press), Apr 2023
Read more -
Walker Morrell et al., Ensuring the Scientific Value and Feasibility of Clinical Trials: A Qualitative Interview Study, AJOB, Jan 2023
Read more -
Jacky Sheng et al., Completeness of clinical evidence citation in trial protocols: A cross-sectional analysis, Med (Cell Press), Apr 2022
Read more
Grant Focus Areas
Share